Amelioration of collagen-induced arthritis and suppression of interferon-γ interleukin-12, and tumor necrosis factor α production by interferon-β gene therapy

Arthritis and Rheumatism

Volumn 42, Issue 1, 1999, Pages 90-99

  Triantaphyllopoulos, Kostas A ^a   Williams, Richard O ^a   Tailor, Hitakshi ^a   Chernajovsky, Yuti ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; COLLAGEN ANTIBODY; GAMMA INTERFERON; INTERLEUKIN 12; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; ARTICLE; DISEASE ACTIVITY; DISEASE SEVERITY; FIBROBLAST; GENE THERAPY; HISTOLOGY; MOUSE; NONHUMAN; PAW EDEMA; PRIORITY JOURNAL; SCORING SYSTEM;

ANIMALS; ANTIBODY FORMATION; ARTHRITIS, EXPERIMENTAL; COLLAGEN; FIBROBLASTS; GENE THERAPY; INTERFERON TYPE II; INTERFERON-BETA; INTERLEUKIN-12; LYMPH NODES; MACROPHAGES; MALE; MICE; MICE, INBRED DBA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032922277     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(199901)42:1<90::AID-ANR12>3.0.CO;2-A     Document Type: Article

References (37)

1. IFNβ MS Study Group. Interferon β-1B is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-61.
2. Triantaphyllopoulos K, Croxford JL, Baker D, Chernajovsky Y. Cloning and expression of murine IFNβ and a TNFα antagonist for retrovirus gene therapy of experimental allergic encephalomyelitis. Gene Ther 1998;5:253-63.
3. Croxford JL, Triantaphyllopoulos K, Podhajcer OL, Feldmann M, Baker D, Chernajovsky Y. Cytokine gene therapy in experimental allergic encephalomyelitis by injection of plasmid DNA-cationic liposome complex into the central nervous system. J Immunol 1998;160:5181-7.
4. Panitch HS, Bever CJ. Clinical trials of interférons in multiple sclerosis: what have we learned? J Neuroimmunol 1993;46:155-64.
5. Panitch HS, Hirsch RL, Haley AS, Johnson KP. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1987;1:893-5.
6. Machold KP, Smolen JS. IFNγ induced exacerbation of systemic lupus crythematosus. J Rheumatol 1990;17:831-2.
7. Arnason BGW. Dayal A, Ou ZX, Jensen MA. Genç K, Reder AT. et al. Mechanisms of action of IFNβ in multiple sclerosis. Springer Semin Immunopathol 1996;18:125-48.
8. Huang Y, Blatt LM, Taylor MW. Type I interferon as an anti-inflammatory agent: inhibition of LPS-induced IL-1β and induction of IL-1ra. J. Interferon Cytokine Res 1995;15:317-21.
9. Ransohoff RM, Devajyothi C, Estes ML, Babcock G. Rudick RA, Frohman EM. et al. IFNβ specifically inhibits IFNγ-induced class II MHC gene transcription in a human astrocytoma cell line. J Neuroimmunol 1991;33:103-12.
10. Devajyothi C, Kalvakolanu I, Babcock GT, Vasavada HA, Howe PH, Ransohoff RM. Inhibition of IFNγ-induced MHC class II gene transcription by IFNβ and type β-1 transforming growth factor in human astrocvtoma cells. J Biol Chem 1993;268:18794-800.
11. Abu-Khabar KS, Armstrong JA, Ho M. Type I interferons (IFN-α and -β) suppress cytotoxin (TNFα and lymphotoxin) production by mitogen-stimulated human peripheral blood mononuclear cell. J Leukoc Biol 1992;52:165-72.
12. Noronha A, Toscas A, Jensen MA. IFNβ decreases T cell activation and IFNγ production in multiple sclerosis. J Neuroimmunol 1993;46:145-54.
13. Jabaily JA. Thompson JS. Effects of interferon β-1B in rheumatoid arthritis: a case report [letter]. Arthritis Rheum 1997;40:1370.
14. Alsalameh S, Manger B, Kern P, Kalden J. New onset of rheumatoid arthritis during interferon β-1B treatment in a patient with multiple sclerosis: comment on the case report by Jahaily and Thompson [letter]. Arthritis Rheum 1998;41:754.
15. Williams RO, Feldmann M, Maini RN. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci U S A 1992;89:9784-8.
16. Elliott MJ, Maini RN, Feldmann M. Long-Fox A. Charles P, Katsikis P, et al. Treatment of rheumatoid arthritis with chimcric monoclonal antibodies to tumor necrosis factor α. Arthritis Rheum 1993;36:1681-90.
17. Chernajovsky Y, Anncnkov A, Herman C, Triantaphyllopoulos K, Gould D, Dreja H, et al. Gene therapy for rheumatoid arthritis: theoretical considerations. Drugs Aging 1998;12:29-41.
18. Chernajovsky Y. Systemic gene therapy of arthritis. In: Robbins PD, Evans CH, editors. Innovative therapies for rheumatoid arthritis. Barcelona: Prous Science. In press.
19. Chernajovsky Y, Adams G, Podhajcer OL, Mueller GM, Robbins PD, Feldmann M. Inhibition of transfer of collagen-induced arthritis into SCID mice by ex vivo infection of spleen cells with retroviruses expressing soluble tumor necrosis factor receptor. Gene Ther 1995;2:731-5.
20. Chernajovsky Y, Adams G, Triantaphyllopoulos K, Ledda MF, Podhajcer OL. Pathogenic lymphoid cells engineered to express TGF beta 1 ameliorate disease in a collagen-induced arthritis model. Gene Ther 1997;4:553-9.
21. Hanahan D. Studies on transformation of E, coli with plasmid. J Mol Biol 1983;166:557-80.
22. Morgenstern JP, Land H. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res 1990;18:3587-96.
23. Almazan G, McKay R. An oligodendrocyte precursor cell line from rat optic nerve. Brain Res 1992;579:234-45.
24. Pear WS, Nolan GP, Scott ML, Baltimore D. Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci U S A 1993;90:8392-6.
25. Chernajovsky Y, Mory Y, Chen L, Marks Z, Novick D, Rubinstein M, et al. Efficient constitutive production of human fibroblast interferon by hamster cells transformed with the IFN-beta 1 gene fused to an SV40 early promoter. DNA 1984;3:297-308.
26. Mauri C, Williams RO, Walmsley M, Feldmann M. Relationship between Th1/Th2 cytokine patterns and the arthritogenic response in collagen-induced arthritis. Eur J Immunol 1996;26:1511-8.
27. Horsfall AC, Butler DM, Marinova L, Warden PJ, Williams RO, Maini RN, et al. Suppression of collagen-induced arthritis by continuous administration of IL-4. J Immunol 1997;159:5687-96.
28. Bessis N, Boissier MC, Ferrara P, Blankenstein T, Fradelizi D, Fournier C. Attenuation of collagen-induced arthritis in mice by treatment with vector cells engineered to secrete intcrleukin-13. Eur J Immunol 1996;26:2399-403.
29. Malfait A-M, Butler DM, Presky DH, Maini RN, Brennan FM, Feldmann M. Blockade of IL-12 during the induction of collagen-induced arthritis markedly attenuates the severity of the arthritis. Clin Exp Immunol 1998;111:377-83.
30. Gidlund M. Örn A, Wigzell H, Senik A, Gresser I. Enhanced NK cell activity in mice injected with interferon and interferon inducers. Nature 1978;273:759-61.
31. Wilson SB, Kent SC, Patton KT, Orban T, Jackson RA, Exley M, et al. Extreme Th 1 bias of invariant V alpha 24J alpha Q T cells in type 1 diabetes. Nature 1998;391:177-81.
32. Yoshimoto T, Paul WE. Cd4(pos). NK1.1(pos) T-cells promptly produce IL-4 in response to in-vivo challenge with anti-cd3. J Exp Med 1994;179:1285-95.
33. Joosten LA, Lubberst E, Helsen MM, van den Berg WB. Dual role of IL-12 in early and late stages of murine collagen type II arthritis. J Immunol 1997;159:4094-102.
34. McRac BL, Scmnani RT, Hayes MP, van Seventer GA. Type I IFNs inhibit dendritic cell IL-12 production and ThI development. J Immunol 1998;160:4298-304.
35. Ghivizzani SC, Lechman ER, Kang R, Tio C. Kolls J, Evans CH, et al. Direct adenovirus-mediated gene transfer of IL-1 and TNF-α soluble receptors to rabbit knees with experimental arthritis has local and distal anti-arthritic effects. Proc Natl Acad Sci USA 1998;95:4613-8.
36. Bandara G, Mueller GM, Galea-Lauri J, Tindal MH, Georgescu HI, Suchanek MK, et al. Intraarticular expression of biologically active IL-1 receptor antagonist protein by ex-vivo gene transfer. Proc Natl Acad Sci U S A 1993;90:10764-8.
37. Aebischer P, Schluep M, Déglon N, Joseph J-M, Hirt L, Heyd B, et al. Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotropic lateral sclerosis patients. Nat Med 1996;2:696-9.